Table 1: Characteristics of 70 patients with RA and without CVD.

CharacteristicsOverall
(n=70)
Female
(n=54)
Male
(n=16)
p
(F vs. M)

Age, years53.9 (13.1)53.6 (12.4)54.3 (10.3)0.8
RA related variables:
Disease duration, years6.9 (3.3)7.0 (3.4)6.3 (3.1)0.4
Low RA activity duration, years4.2 (1.2)4.2 (1.2)4.0 (1.0)0.6
Positive RF-IgM54 (77.1)41 (75.9)13 (81.3)0.7
Positive anti-CCP53 (75.7)40 (74.1)13 (81.3)0.6
Erosions (hands/feet)37 (52.9)28 (51.9)9 (56.3)0.8
Extra-articular manifestations14 (22.9)12 (22.2)2 (12.5)0.4
DAS282.87 (0.2)2.88 (0.2)2.83 (0.23)0.4
CRP, mg/l8.7 (12.9)7.9 (6.8)11.4 (24.3)0.3
ESR, mm/h14.8 (10.2)15.8 (10.1)11.3 (9.7)0.1
Treatment:
Current glucocorticoid use16 (22.8)15 (27.8)1 (6.3)0.07
Current conventional DMARD70 (100)54 (100)16 (100)
MTX monotherapy47 (67.1)33 (61.1)14 (87.4)0.3
LEF monotherapy11 (15.7)10 (18.5)1 (6.3)
HCQ monotherapy5 (7.2)4 (7.4)0
SS monotherapy1 (1.4)1 (1.9)0
CsA monotherapy1 (1.4)1 (1.9)0
DMARDs combination5 (7.2)5 (9.2)1 (6.3)

Data are presented as mean (SD) (range) or number (%).
Abbreviations: anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; CVD, cardiovascular disease; CsA, cyclosporine A; DAS28, disease activity score in 28 joints; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; RF-IgM, IgM rheumatoid factor; SS, sulfasalazine.